RT Journal Article
SR Electronic
T1 Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.12.22273745
DO 10.1101/2022.04.12.22273745
A1 Bansal, Devendra
A1 Abdulmajeed, Jazeel
A1 Yassin, Esraa
A1 Al-Shamali, Maha H M A
A1 Albayat, Soha S A
A1 Himatt, Sayed M
A1 Cyprian, Farhan S
A1 Chivese, Tawanda
A1 Mundodan, Jesha M A
A1 Khogali, Hayat
A1 Baaboura, Rekayahouda
A1 Kaleeckal, Anvar H
A1 Kandy, Mujeeb C
A1 Latif, Ali Nizar
A1 Al-Kuwari, Mohamed G
A1 Al-Romaihi, Hamad Eid
A1 Khal, Abdullatif Al
A1 Bertollini, Roberto
A1 Al-Thani, Mohamed H
A1 Farag, Elmobashar
A1 Doi, Suhail A R
YR 2022
UL http://medrxiv.org/content/early/2022/04/18/2022.04.12.22273745.abstract
AB Background Waning immunity following administration of mRNA based COVID-19 vaccines remains a concern for many health systems. We undertook a study of SARS-CoV-2 infections, with and without requirement for intensive care to shed more light on the duration of vaccine effectiveness for protection against the need for intensive care.Methods We used a matched case-control study design with the study base being all individuals with first infection with SARS-CoV-2 reported in the State of Qatar between 1 Jan 2021 and 20 Feb 2022. Cases were those requiring intensive care while controls were those who recovered without need for intensive care. Vaccine effectiveness against requiring intensive care and number needed to vaccinate (NNV) to prevent one more case of COVID-19 requiring intensive care were computed for the mRNA (BNT162b2 / mRNA-1273) vaccines.Results Vaccine effectiveness against requiring intensive care was 59% (95% confidence interval [CI], 50 to 76) between the first and second dose and strengthened to 89% (95% CI, 85 to 92) between the second dose and 4 months post the second dose in persons who received a primary course of the vaccine. There was no waning of vaccine effectiveness in the period from 4 to 12 months after the second dose.Conclusions This study demonstrates that vaccine effectiveness against requiring intensive care remains robust till at least 12 months after the second dose of mRNA based vaccines.Competing Interest StatementThe authors have declared no competing interest.Funding StatementData collected as part of routine surveillance at the Ministry of Public Health was analyzed as part of this study. No separate funds were available for this study. There are no funding sources for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval for the study was obtained (ERC-826-3-2020) and waiver of informed consent was given by the Health Research Governance Department at the Ministry of Public Health, QatarI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are summarized in the manuscript